 | • レポートコード：MRC2-11QY01111 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、118ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はヘモグロビン症治療薬のグローバル市場について調査・分析したレポートです。種類別（サラセミア療法、鎌状赤血球症（SCD）療法、その他）市場規模、用途別（アルファサラセミア、ベータサラセミア、鎌状赤血球症、Hb変異型疾患）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別ヘモグロビン症治療薬の競争状況、市場シェア ・世界のヘモグロビン症治療薬市場：種類別市場規模 2015年-2020年（サラセミア療法、鎌状赤血球症（SCD）療法、その他） ・世界のヘモグロビン症治療薬市場：種類別市場規模予測 2021年-2026年（サラセミア療法、鎌状赤血球症（SCD）療法、その他） ・世界のヘモグロビン症治療薬市場：用途別市場規模 2015年-2020年（アルファサラセミア、ベータサラセミア、鎌状赤血球症、Hb変異型疾患） ・世界のヘモグロビン症治療薬市場：用途別市場規模予測 2021年-2026年（アルファサラセミア、ベータサラセミア、鎌状赤血球症、Hb変異型疾患） ・北米のヘモグロビン症治療薬市場分析：米国、カナダ ・ヨーロッパのヘモグロビン症治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのヘモグロビン症治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のヘモグロビン症治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのヘモグロビン症治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Gamida Cell、Alnylam Pharmaceuticals、Biogen Idec、Sangamo BioSciences Inc.、Genetix Pharmaceuticals/Bluebird Bio、Global Blood Therapeutics Inc.、Pfizer Inc.、Mast Therapeutics、Emmaus Life Sciences, Inc.、Prolong Pharmaceuticals、Celgene Corporation、HemaQuest Pharmaceuticals ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Hemoglobinopathies Drugs Market
The global Hemoglobinopathies Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Hemoglobinopathies Drugs Scope and Market Size
Hemoglobinopathies Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hemoglobinopathies Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Hemoglobinopathies Drugs market is segmented into
Thalassemia Therapy
Sickle Cell Disease(SCD) Therapy
Other Therapy
Segment by Application, the Hemoglobinopathies Drugs market is segmented into
Alpha Thalassemia
Beta thalassemia
Sickle Cell Disease
Hb Variants Diseases
Regional and Country-level Analysis
The Hemoglobinopathies Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Hemoglobinopathies Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Hemoglobinopathies Drugs Market Share Analysis
Hemoglobinopathies Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Hemoglobinopathies Drugs business, the date to enter into the Hemoglobinopathies Drugs market, Hemoglobinopathies Drugs product introduction, recent developments, etc.
The major vendors covered:
Gamida Cell
Alnylam Pharmaceuticals
Biogen Idec
Sangamo BioSciences Inc.
Genetix Pharmaceuticals/Bluebird Bio
Global Blood Therapeutics Inc.
Pfizer Inc.
Mast Therapeutics
Emmaus Life Sciences, Inc.
Prolong Pharmaceuticals
Celgene Corporation
HemaQuest Pharmaceuticals
1 Study Coverage
1.1 Hemoglobinopathies Drugs Product Introduction
1.2 Market Segments
1.3 Key Hemoglobinopathies Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Hemoglobinopathies Drugs Market Size Growth Rate by Type
1.4.2 Thalassemia Therapy
1.4.3 Sickle Cell Disease(SCD) Therapy
1.4.4 Other Therapy
1.5 Market by Application
1.5.1 Global Hemoglobinopathies Drugs Market Size Growth Rate by Application
1.5.2 Alpha Thalassemia
1.5.3 Beta thalassemia
1.5.4 Sickle Cell Disease
1.5.5 Hb Variants Diseases
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Hemoglobinopathies Drugs Market Size, Estimates and Forecasts
2.1.1 Global Hemoglobinopathies Drugs Revenue 2015-2026
2.1.2 Global Hemoglobinopathies Drugs Sales 2015-2026
2.2 Global Hemoglobinopathies Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Hemoglobinopathies Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Hemoglobinopathies Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Hemoglobinopathies Drugs Competitor Landscape by Players
3.1 Hemoglobinopathies Drugs Sales by Manufacturers
3.1.1 Hemoglobinopathies Drugs Sales by Manufacturers (2015-2020)
3.1.2 Hemoglobinopathies Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Hemoglobinopathies Drugs Revenue by Manufacturers
3.2.1 Hemoglobinopathies Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Hemoglobinopathies Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Hemoglobinopathies Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Hemoglobinopathies Drugs Revenue in 2019
3.2.5 Global Hemoglobinopathies Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Hemoglobinopathies Drugs Price by Manufacturers
3.4 Hemoglobinopathies Drugs Manufacturing Base Distribution, Product Types
3.4.1 Hemoglobinopathies Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hemoglobinopathies Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Hemoglobinopathies Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hemoglobinopathies Drugs Market Size by Type (2015-2020)
4.1.1 Global Hemoglobinopathies Drugs Sales by Type (2015-2020)
4.1.2 Global Hemoglobinopathies Drugs Revenue by Type (2015-2020)
4.1.3 Hemoglobinopathies Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Hemoglobinopathies Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Hemoglobinopathies Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Hemoglobinopathies Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Hemoglobinopathies Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Hemoglobinopathies Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Hemoglobinopathies Drugs Market Size by Application (2015-2020)
5.1.1 Global Hemoglobinopathies Drugs Sales by Application (2015-2020)
5.1.2 Global Hemoglobinopathies Drugs Revenue by Application (2015-2020)
5.1.3 Hemoglobinopathies Drugs Price by Application (2015-2020)
5.2 Hemoglobinopathies Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Hemoglobinopathies Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Hemoglobinopathies Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Hemoglobinopathies Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Hemoglobinopathies Drugs by Country
6.1.1 North America Hemoglobinopathies Drugs Sales by Country
6.1.2 North America Hemoglobinopathies Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Hemoglobinopathies Drugs Market Facts & Figures by Type
6.3 North America Hemoglobinopathies Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Hemoglobinopathies Drugs by Country
7.1.1 Europe Hemoglobinopathies Drugs Sales by Country
7.1.2 Europe Hemoglobinopathies Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Hemoglobinopathies Drugs Market Facts & Figures by Type
7.3 Europe Hemoglobinopathies Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Hemoglobinopathies Drugs by Region
8.1.1 Asia Pacific Hemoglobinopathies Drugs Sales by Region
8.1.2 Asia Pacific Hemoglobinopathies Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Hemoglobinopathies Drugs Market Facts & Figures by Type
8.3 Asia Pacific Hemoglobinopathies Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Hemoglobinopathies Drugs by Country
9.1.1 Latin America Hemoglobinopathies Drugs Sales by Country
9.1.2 Latin America Hemoglobinopathies Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Hemoglobinopathies Drugs Market Facts & Figures by Type
9.3 Central & South America Hemoglobinopathies Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Hemoglobinopathies Drugs by Country
10.1.1 Middle East and Africa Hemoglobinopathies Drugs Sales by Country
10.1.2 Middle East and Africa Hemoglobinopathies Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Hemoglobinopathies Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Hemoglobinopathies Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Gamida Cell
11.1.1 Gamida Cell Corporation Information
11.1.2 Gamida Cell Description and Business Overview
11.1.3 Gamida Cell Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Gamida Cell Hemoglobinopathies Drugs Products Offered
11.1.5 Gamida Cell Related Developments
11.2 Alnylam Pharmaceuticals
11.2.1 Alnylam Pharmaceuticals Corporation Information
11.2.2 Alnylam Pharmaceuticals Description and Business Overview
11.2.3 Alnylam Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Alnylam Pharmaceuticals Hemoglobinopathies Drugs Products Offered
11.2.5 Alnylam Pharmaceuticals Related Developments
11.3 Biogen Idec
11.3.1 Biogen Idec Corporation Information
11.3.2 Biogen Idec Description and Business Overview
11.3.3 Biogen Idec Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Biogen Idec Hemoglobinopathies Drugs Products Offered
11.3.5 Biogen Idec Related Developments
11.4 Sangamo BioSciences Inc.
11.4.1 Sangamo BioSciences Inc. Corporation Information
11.4.2 Sangamo BioSciences Inc. Description and Business Overview
11.4.3 Sangamo BioSciences Inc. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Sangamo BioSciences Inc. Hemoglobinopathies Drugs Products Offered
11.4.5 Sangamo BioSciences Inc. Related Developments
11.5 Genetix Pharmaceuticals/Bluebird Bio
11.5.1 Genetix Pharmaceuticals/Bluebird Bio Corporation Information
11.5.2 Genetix Pharmaceuticals/Bluebird Bio Description and Business Overview
11.5.3 Genetix Pharmaceuticals/Bluebird Bio Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Products Offered
11.5.5 Genetix Pharmaceuticals/Bluebird Bio Related Developments
11.6 Global Blood Therapeutics Inc.
11.6.1 Global Blood Therapeutics Inc. Corporation Information
11.6.2 Global Blood Therapeutics Inc. Description and Business Overview
11.6.3 Global Blood Therapeutics Inc. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Products Offered
11.6.5 Global Blood Therapeutics Inc. Related Developments
11.7 Pfizer Inc.
11.7.1 Pfizer Inc. Corporation Information
11.7.2 Pfizer Inc. Description and Business Overview
11.7.3 Pfizer Inc. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Pfizer Inc. Hemoglobinopathies Drugs Products Offered
11.7.5 Pfizer Inc. Related Developments
11.8 Mast Therapeutics
11.8.1 Mast Therapeutics Corporation Information
11.8.2 Mast Therapeutics Description and Business Overview
11.8.3 Mast Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Mast Therapeutics Hemoglobinopathies Drugs Products Offered
11.8.5 Mast Therapeutics Related Developments
11.9 Emmaus Life Sciences, Inc.
11.9.1 Emmaus Life Sciences, Inc. Corporation Information
11.9.2 Emmaus Life Sciences, Inc. Description and Business Overview
11.9.3 Emmaus Life Sciences, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Products Offered
11.9.5 Emmaus Life Sciences, Inc. Related Developments
11.10 Prolong Pharmaceuticals
11.10.1 Prolong Pharmaceuticals Corporation Information
11.10.2 Prolong Pharmaceuticals Description and Business Overview
11.10.3 Prolong Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Prolong Pharmaceuticals Hemoglobinopathies Drugs Products Offered
11.10.5 Prolong Pharmaceuticals Related Developments
11.1 Gamida Cell
11.1.1 Gamida Cell Corporation Information
11.1.2 Gamida Cell Description and Business Overview
11.1.3 Gamida Cell Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Gamida Cell Hemoglobinopathies Drugs Products Offered
11.1.5 Gamida Cell Related Developments
11.12 HemaQuest Pharmaceuticals
11.12.1 HemaQuest Pharmaceuticals Corporation Information
11.12.2 HemaQuest Pharmaceuticals Description and Business Overview
11.12.3 HemaQuest Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.12.4 HemaQuest Pharmaceuticals Products Offered
11.12.5 HemaQuest Pharmaceuticals Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Hemoglobinopathies Drugs Market Estimates and Projections by Region
12.1.1 Global Hemoglobinopathies Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Hemoglobinopathies Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Hemoglobinopathies Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Hemoglobinopathies Drugs Sales Forecast (2021-2026)
12.2.2 North America: Hemoglobinopathies Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Hemoglobinopathies Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Hemoglobinopathies Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Hemoglobinopathies Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Hemoglobinopathies Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Hemoglobinopathies Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Hemoglobinopathies Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Hemoglobinopathies Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Hemoglobinopathies Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Hemoglobinopathies Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Hemoglobinopathies Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Hemoglobinopathies Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Hemoglobinopathies Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Hemoglobinopathies Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Hemoglobinopathies Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Hemoglobinopathies Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Hemoglobinopathies Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Hemoglobinopathies Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Hemoglobinopathies Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Hemoglobinopathies Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Hemoglobinopathies Drugs Market Segments
Table 2. Ranking of Global Top Hemoglobinopathies Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Hemoglobinopathies Drugs Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Thalassemia Therapy
Table 5. Major Manufacturers of Sickle Cell Disease(SCD) Therapy
Table 6. Major Manufacturers of Other Therapy
Table 7. Global Hemoglobinopathies Drugs Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 8. Global Hemoglobinopathies Drugs Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 9. Global Hemoglobinopathies Drugs Sales by Regions 2015-2020 (K Pcs)
Table 10. Global Hemoglobinopathies Drugs Sales Market Share by Regions (2015-2020)
Table 11. Global Hemoglobinopathies Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 12. Global Hemoglobinopathies Drugs Sales by Manufacturers (2015-2020) (K Pcs)
Table 13. Global Hemoglobinopathies Drugs Sales Share by Manufacturers (2015-2020)
Table 14. Global Hemoglobinopathies Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 15. Global Hemoglobinopathies Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hemoglobinopathies Drugs as of 2019)
Table 16. Hemoglobinopathies Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 17. Hemoglobinopathies Drugs Revenue Share by Manufacturers (2015-2020)
Table 18. Key Manufacturers Hemoglobinopathies Drugs Price (2015-2020) (USD/Pcs)
Table 19. Hemoglobinopathies Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers Hemoglobinopathies Drugs Product Type
Table 21. Date of International Manufacturers Enter into Hemoglobinopathies Drugs Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Global Hemoglobinopathies Drugs Sales by Type (2015-2020) (K Pcs)
Table 24. Global Hemoglobinopathies Drugs Sales Share by Type (2015-2020)
Table 25. Global Hemoglobinopathies Drugs Revenue by Type (2015-2020) (US$ Million)
Table 26. Global Hemoglobinopathies Drugs Revenue Share by Type (2015-2020)
Table 27. Hemoglobinopathies Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 28. Global Hemoglobinopathies Drugs Sales by Application (2015-2020) (K Pcs)
Table 29. Global Hemoglobinopathies Drugs Sales Share by Application (2015-2020)
Table 30. North America Hemoglobinopathies Drugs Sales by Country (2015-2020) (K Pcs)
Table 31. North America Hemoglobinopathies Drugs Sales Market Share by Country (2015-2020)
Table 32. North America Hemoglobinopathies Drugs Revenue by Country (2015-2020) (US$ Million)
Table 33. North America Hemoglobinopathies Drugs Revenue Market Share by Country (2015-2020)
Table 34. North America Hemoglobinopathies Drugs Sales by Type (2015-2020) (K Pcs)
Table 35. North America Hemoglobinopathies Drugs Sales Market Share by Type (2015-2020)
Table 36. North America Hemoglobinopathies Drugs Sales by Application (2015-2020) (K Pcs)
Table 37. North America Hemoglobinopathies Drugs Sales Market Share by Application (2015-2020)
Table 38. Europe Hemoglobinopathies Drugs Sales by Country (2015-2020) (K Pcs)
Table 39. Europe Hemoglobinopathies Drugs Sales Market Share by Country (2015-2020)
Table 40. Europe Hemoglobinopathies Drugs Revenue by Country (2015-2020) (US$ Million)
Table 41. Europe Hemoglobinopathies Drugs Revenue Market Share by Country (2015-2020)
Table 42. Europe Hemoglobinopathies Drugs Sales by Type (2015-2020) (K Pcs)
Table 43. Europe Hemoglobinopathies Drugs Sales Market Share by Type (2015-2020)
Table 44. Europe Hemoglobinopathies Drugs Sales by Application (2015-2020) (K Pcs)
Table 45. Europe Hemoglobinopathies Drugs Sales Market Share by Application (2015-2020)
Table 46. Asia Pacific Hemoglobinopathies Drugs Sales by Region (2015-2020) (K Pcs)
Table 47. Asia Pacific Hemoglobinopathies Drugs Sales Market Share by Region (2015-2020)
Table 48. Asia Pacific Hemoglobinopathies Drugs Revenue by Region (2015-2020) (US$ Million)
Table 49. Asia Pacific Hemoglobinopathies Drugs Revenue Market Share by Region (2015-2020)
Table 50. Asia Pacific Hemoglobinopathies Drugs Sales by Type (2015-2020) (K Pcs)
Table 51. Asia Pacific Hemoglobinopathies Drugs Sales Market Share by Type (2015-2020)
Table 52. Asia Pacific Hemoglobinopathies Drugs Sales by Application (2015-2020) (K Pcs)
Table 53. Asia Pacific Hemoglobinopathies Drugs Sales Market Share by Application (2015-2020)
Table 54. Latin America Hemoglobinopathies Drugs Sales by Country (2015-2020) (K Pcs)
Table 55. Latin America Hemoglobinopathies Drugs Sales Market Share by Country (2015-2020)
Table 56. Latin Americaa Hemoglobinopathies Drugs Revenue by Country (2015-2020) (US$ Million)
Table 57. Latin America Hemoglobinopathies Drugs Revenue Market Share by Country (2015-2020)
Table 58. Latin America Hemoglobinopathies Drugs Sales by Type (2015-2020) (K Pcs)
Table 59. Latin America Hemoglobinopathies Drugs Sales Market Share by Type (2015-2020)
Table 60. Latin America Hemoglobinopathies Drugs Sales by Application (2015-2020) (K Pcs)
Table 61. Latin America Hemoglobinopathies Drugs Sales Market Share by Application (2015-2020)
Table 62. Middle East and Africa Hemoglobinopathies Drugs Sales by Country (2015-2020) (K Pcs)
Table 63. Middle East and Africa Hemoglobinopathies Drugs Sales Market Share by Country (2015-2020)
Table 64. Middle East and Africa Hemoglobinopathies Drugs Revenue by Country (2015-2020) (US$ Million)
Table 65. Middle East and Africa Hemoglobinopathies Drugs Revenue Market Share by Country (2015-2020)
Table 66. Middle East and Africa Hemoglobinopathies Drugs Sales by Type (2015-2020) (K Pcs)
Table 67. Middle East and Africa Hemoglobinopathies Drugs Sales Market Share by Type (2015-2020)
Table 68. Middle East and Africa Hemoglobinopathies Drugs Sales by Application (2015-2020) (K Pcs)
Table 69. Middle East and Africa Hemoglobinopathies Drugs Sales Market Share by Application (2015-2020)
Table 70. Gamida Cell Corporation Information
Table 71. Gamida Cell Description and Major Businesses
Table 72. Gamida Cell Hemoglobinopathies Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 73. Gamida Cell Product
Table 74. Gamida Cell Recent Development
Table 75. Alnylam Pharmaceuticals Corporation Information
Table 76. Alnylam Pharmaceuticals Description and Major Businesses
Table 77. Alnylam Pharmaceuticals Hemoglobinopathies Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Alnylam Pharmaceuticals Product
Table 79. Alnylam Pharmaceuticals Recent Development
Table 80. Biogen Idec Corporation Information
Table 81. Biogen Idec Description and Major Businesses
Table 82. Biogen Idec Hemoglobinopathies Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. Biogen Idec Product
Table 84. Biogen Idec Recent Development
Table 85. Sangamo BioSciences Inc. Corporation Information
Table 86. Sangamo BioSciences Inc. Description and Major Businesses
Table 87. Sangamo BioSciences Inc. Hemoglobinopathies Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. Sangamo BioSciences Inc. Product
Table 89. Sangamo BioSciences Inc. Recent Development
Table 90. Genetix Pharmaceuticals/Bluebird Bio Corporation Information
Table 91. Genetix Pharmaceuticals/Bluebird Bio Description and Major Businesses
Table 92. Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. Genetix Pharmaceuticals/Bluebird Bio Product
Table 94. Genetix Pharmaceuticals/Bluebird Bio Recent Development
Table 95. Global Blood Therapeutics Inc. Corporation Information
Table 96. Global Blood Therapeutics Inc. Description and Major Businesses
Table 97. Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. Global Blood Therapeutics Inc. Product
Table 99. Global Blood Therapeutics Inc. Recent Development
Table 100. Pfizer Inc. Corporation Information
Table 101. Pfizer Inc. Description and Major Businesses
Table 102. Pfizer Inc. Hemoglobinopathies Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. Pfizer Inc. Product
Table 104. Pfizer Inc. Recent Development
Table 105. Mast Therapeutics Corporation Information
Table 106. Mast Therapeutics Description and Major Businesses
Table 107. Mast Therapeutics Hemoglobinopathies Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. Mast Therapeutics Product
Table 109. Mast Therapeutics Recent Development
Table 110. Emmaus Life Sciences, Inc. Corporation Information
Table 111. Emmaus Life Sciences, Inc. Description and Major Businesses
Table 112. Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 113. Emmaus Life Sciences, Inc. Product
Table 114. Emmaus Life Sciences, Inc. Recent Development
Table 115. Prolong Pharmaceuticals Corporation Information
Table 116. Prolong Pharmaceuticals Description and Major Businesses
Table 117. Prolong Pharmaceuticals Hemoglobinopathies Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 118. Prolong Pharmaceuticals Product
Table 119. Prolong Pharmaceuticals Recent Development
Table 120. Celgene Corporation Corporation Information
Table 121. Celgene Corporation Description and Major Businesses
Table 122. Celgene Corporation Hemoglobinopathies Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 123. Celgene Corporation Product
Table 124. Celgene Corporation Recent Development
Table 125. HemaQuest Pharmaceuticals Corporation Information
Table 126. HemaQuest Pharmaceuticals Description and Major Businesses
Table 127. HemaQuest Pharmaceuticals Hemoglobinopathies Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 128. HemaQuest Pharmaceuticals Product
Table 129. HemaQuest Pharmaceuticals Recent Development
Table 130. Global Hemoglobinopathies Drugs Sales Forecast by Regions (2021-2026) (K Pcs)
Table 131. Global Hemoglobinopathies Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 132. Global Hemoglobinopathies Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 133. Global Hemoglobinopathies Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 134. North America: Hemoglobinopathies Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 135. North America: Hemoglobinopathies Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 136. Europe: Hemoglobinopathies Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 137. Europe: Hemoglobinopathies Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 138. Asia Pacific: Hemoglobinopathies Drugs Sales Forecast by Region (2021-2026) (K Pcs)
Table 139. Asia Pacific: Hemoglobinopathies Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 140. Latin America: Hemoglobinopathies Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 141. Latin America: Hemoglobinopathies Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 142. Middle East and Africa: Hemoglobinopathies Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 143. Middle East and Africa: Hemoglobinopathies Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 144. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 145. Key Challenges
Table 146. Market Risks
Table 147. Main Points Interviewed from Key Hemoglobinopathies Drugs Players
Table 148. Hemoglobinopathies Drugs Customers List
Table 149. Hemoglobinopathies Drugs Distributors List
Table 150. Research Programs/Design for This Report
Table 151. Key Data Information from Secondary Sources
Table 152. Key Data Information from Primary Sources
List of Figures
Figure 1. Hemoglobinopathies Drugs Product Picture
Figure 2. Global Hemoglobinopathies Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Thalassemia Therapy Product Picture
Figure 4. Sickle Cell Disease(SCD) Therapy Product Picture
Figure 5. Other Therapy Product Picture
Figure 6. Global Hemoglobinopathies Drugs Sales Market Share by Application in 2020 & 2026
Figure 7. Alpha Thalassemia
Figure 8. Beta thalassemia
Figure 9. Sickle Cell Disease
Figure 10. Hb Variants Diseases
Figure 11. Hemoglobinopathies Drugs Report Years Considered
Figure 12. Global Hemoglobinopathies Drugs Market Size 2015-2026 (US$ Million)
Figure 13. Global Hemoglobinopathies Drugs Sales 2015-2026 (K Pcs)
Figure 14. Global Hemoglobinopathies Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Hemoglobinopathies Drugs Sales Market Share by Region (2015-2020)
Figure 16. Global Hemoglobinopathies Drugs Sales Market Share by Region in 2019
Figure 17. Global Hemoglobinopathies Drugs Revenue Market Share by Region (2015-2020)
Figure 18. Global Hemoglobinopathies Drugs Revenue Market Share by Region in 2019
Figure 19. Global Hemoglobinopathies Drugs Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Hemoglobinopathies Drugs Revenue in 2019
Figure 21. Hemoglobinopathies Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Hemoglobinopathies Drugs Sales Market Share by Type (2015-2020)
Figure 23. Global Hemoglobinopathies Drugs Sales Market Share by Type in 2019
Figure 24. Global Hemoglobinopathies Drugs Revenue Market Share by Type (2015-2020)
Figure 25. Global Hemoglobinopathies Drugs Revenue Market Share by Type in 2019
Figure 26. Global Hemoglobinopathies Drugs Market Share by Price Range (2015-2020)
Figure 27. Global Hemoglobinopathies Drugs Sales Market Share by Application (2015-2020)
Figure 28. Global Hemoglobinopathies Drugs Sales Market Share by Application in 2019
Figure 29. Global Hemoglobinopathies Drugs Revenue Market Share by Application (2015-2020)
Figure 30. Global Hemoglobinopathies Drugs Revenue Market Share by Application in 2019
Figure 31. North America Hemoglobinopathies Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 32. North America Hemoglobinopathies Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Hemoglobinopathies Drugs Sales Market Share by Country in 2019
Figure 34. North America Hemoglobinopathies Drugs Revenue Market Share by Country in 2019
Figure 35. U.S. Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 36. U.S. Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. Canada Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Hemoglobinopathies Drugs Market Share by Type in 2019
Figure 40. North America Hemoglobinopathies Drugs Market Share by Application in 2019
Figure 41. Europe Hemoglobinopathies Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 42. Europe Hemoglobinopathies Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Hemoglobinopathies Drugs Sales Market Share by Country in 2019
Figure 44. Europe Hemoglobinopathies Drugs Revenue Market Share by Country in 2019
Figure 45. Germany Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 46. Germany Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. France Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. U.K. Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. Italy Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Russia Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Hemoglobinopathies Drugs Market Share by Type in 2019
Figure 56. Europe Hemoglobinopathies Drugs Market Share by Application in 2019
Figure 57. Asia Pacific Hemoglobinopathies Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 58. Asia Pacific Hemoglobinopathies Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Hemoglobinopathies Drugs Sales Market Share by Region in 2019
Figure 60. Asia Pacific Hemoglobinopathies Drugs Revenue Market Share by Region in 2019
Figure 61. China Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 62. China Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. Japan Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. South Korea Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. India Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. Australia Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Taiwan Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Indonesia Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Thailand Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Malaysia Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Philippines Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Vietnam Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Hemoglobinopathies Drugs Market Share by Type in 2019
Figure 84. Asia Pacific Hemoglobinopathies Drugs Market Share by Application in 2019
Figure 85. Latin America Hemoglobinopathies Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 86. Latin America Hemoglobinopathies Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Hemoglobinopathies Drugs Sales Market Share by Country in 2019
Figure 88. Latin America Hemoglobinopathies Drugs Revenue Market Share by Country in 2019
Figure 89. Mexico Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 90. Mexico Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Brazil Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Argentina Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Hemoglobinopathies Drugs Market Share by Type in 2019
Figure 96. Latin America Hemoglobinopathies Drugs Market Share by Application in 2019
Figure 97. Middle East and Africa Hemoglobinopathies Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 98. Middle East and Africa Hemoglobinopathies Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Hemoglobinopathies Drugs Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Hemoglobinopathies Drugs Revenue Market Share by Country in 2019
Figure 101. Turkey Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 102. Turkey Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Saudi Arabia Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Hemoglobinopathies Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. U.A.E Hemoglobinopathies Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Hemoglobinopathies Drugs Market Share by Type in 2019
Figure 108. Middle East and Africa Hemoglobinopathies Drugs Market Share by Application in 2019
Figure 109. North America Hemoglobinopathies Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 110. North America Hemoglobinopathies Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Hemoglobinopathies Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. Europe Hemoglobinopathies Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Hemoglobinopathies Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Asia Pacific Hemoglobinopathies Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Hemoglobinopathies Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Latin America Hemoglobinopathies Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Hemoglobinopathies Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Middle East and Africa Hemoglobinopathies Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed
画期的治療薬の世界市場（～2026年） Breakthrough therapy drugs are intended to treat serious and life-threatening conditions. The breakthrough therapy is the designation given by FDA for the drugs when there is a preliminary clinical evidence indicates that the drug proves a substantial improvement over available drug treatment. Two f…- 鎌状赤血球の世界市場（～2026年） The global sickle cell market is expected to grow in future due to rising African-American population, economic growth, increasing healthcare expenditure and prevalence of sickle cell. Key trends of this market include progressing drug pipeline and rising research grants. However, there are some fac…
- クラッベ病治療薬の世界市場（～2026年） Krabbe disease is an uncommon and typically deadly concern of the nervous system. It is an acquired hereditary sickness, which implies that it is passed down in families. Individuals with Krabbe disease are not able to make a sufficient substance called galactosylceramidase, which is expected to mak…
- 泌尿生殖器治療薬の世界市場（～2026年） A medical science concerned with the study and treatment of diseases of the genital and urinary organs, especially sexually transmitted diseases. The growing prevalence of genitourinary disorders is presumed to be the high rendering impact driver of this vertical. In addition, increasing number of p…
- 腎細胞がん治療薬の世界市場（～2026年） Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases.The drug is …